Astria Therapeutics Inc expected to post a loss of 55 cents a share - Earnings Preview

Astria Therapeutics

09/05/2023 03:02

* Astria Therapeutics Inc  ATXS.OQ   ATXS.O  is expected
to show
no change in quarterly revenue when it reports  results on May
10 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Astria Therapeutics
Inc
is for a loss of 55 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 7 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Astria
Therapeutics Inc is $23​, above​ its last closing price
of $12.63. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.57       -0.71      -0.72     Missed  -1.2
 Sep. 30 2022  -0.91       -0.92      -0.87     Beat    5.2
 Jun. 30 2022  -0.99       -1.01      -0.86     Beat    15.3​
 Mar. 31 2022  -0.72       -0.73      -1.18     Missed  -62.1
 ​​Dec.        -0.68       -0.66      -11.00    Missed  -1,566
 31 2021                                                .7
 Sep. 30 2021  -0.76       -0.77      -0.61     Beat    21​
 Jun. 30 2021  -1.88       -1.82      -1.26     Beat    30.8
 Mar. 31 2021  -0.86       -0.92      -1.44     Missed  -56.5
 This summary was machine generated May 9 at 02:02 GMT.  All
figures in US dollars  unless otherwise stated